How to Check the Quality of Your Stocks: Financial Health

Published 09-10-2023, 10:33 am

While judging the financial health of your stocks, it is imperative to look at the holistic picture and not just a few parameters. Factors that could help you determine how well your stock is doing could be its free cash flows, bottom line performance, revenue trend, price momentum, debt levels, fluctuation in the EPS, and so on.

In fact, these parameters are not even close to the count that must be considered for the broader picture. This is where the “Financial Health” tool of InvestingPro+ comes to the rescue which does all the job of analyzing the stock and gives a score (rating) to each of them.

Let us take the example of Infosys Limited (NS:INFY), the second-largest IT company in India with a market capitalization of INR 6,11,981 crore.

  1. Cash Flow Health - 3.25/5

As can be seen from the image below, the tool has analyzed all the ratios that help to make a judgment of the cash flow situation of the company such as asset turnover, interest coverage, quick ratio, etc., and gave a score out of 5 to each one. The final score has been calculated by taking the average of all, which is 3.25/5.

What we need to make sure is, the average does not go below 3.

  1. Growth Health - 2.96/5

Growth parameters such as EPS trend, gross profit, revenue growth, operating income, etc are taken into consideration for a health check on the growth aspect of the company. The avg. score is 2.96, which is good as it’s almost 3.

We consider a score of 3 to be the benchmark and slipping below which is a sign of caution. Another thing to note, the growth in the entire IT industry has slowed down over the past few months, hence there’s nothing specifically wrong with the counter. Also, if you look at the EPS trend score, which is 5, gives us the convection of the intact growth.

  1. Price Momentum - 3.23/5

If investors also blend some aspects of technicals into their fundamentally strong picks, they can do noticeably better and hence the price momentum is also included in the overall quality of the stock. Simply, it does not make sense to hold strong stocks in the portfolio if they haven’t been moving an inch for the last many months.

There’s always an opportunity cost to pay and therefore we don’t want laggards to be in the portfolio. The tool calculates the price momentum over various time frames and gives a score for every time frame, the average is then taken to arrive at the final momentum score. This metric alone can be used to pick high-momentum stocks in the portfolio, irrespective of their fundamentals, something which I do often. The time frames can also be excluded as per the liking of the investor.

  1. Profitability Health - 4.45/5

This is an important area to focus on. Luckily, Infosys has a score of 4.45 here. The bottom line is extremely important for a company and this is what most shareholders are concerned about.

If you look at the parameters here, most of them have an individual score of over 4. Hence, investors can sit for the long term till the ongoing difficult time for the IT space passes by. This metric can help to stay the course.

  1. Relative Value - 2.6/5

The last but one of the most imp. parameters is the valuation relative to the peers. No matter how good the counter is, it is imperative to buy when the valuations are comforting to not just have a higher potential for profitability but also to increase the margin of safety.

This is where Infosys is looking weak with a score of 2.6. This simply implies that there are other lucrative opportunities in the market if investors are willing to take exposure to the IT space. So investors who are waiting to buy Infosys shares can wait for the ratings to improve.

Now, with some parameters good and some not-so-good, how would you decide whether Infosys is a good portfolio stock or not? The answer lies in eliminating the extreme ends via averages. The final financial health score is taken as the average of the scores of all 5 above-mentioned parameters. This final figure is the “Ultimate Health Check” for your stock, which is 4 in the case of Infosys. As long as this score is at or above 3, you can keep holding your stock.

This is how I do a quick health check of the stocks I hold in my portfolio and stay informed about when to exit them.

This has been covered in my previous webinar on 27 September 2023. You can access the recording here: https://t.co/tU1TtzWfl4

Remember, the massive offer of a 65% discount on InvestingPro+ via the coupon code PROW478 is only valid till 10 October 2023. Here's the payment link: https://t.co/QLfmyGqtRA

For any assistance reach me out at aayush.k@investing.com or on X (formerly, Twitter) - aayushxkhanna

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.